Skip to content Skip to footer
Subscribe Now

INSIGHTS+

Disease of the Month - Duchenne Muscular Dystrophy (DMD)
Disease of the Month – Duchenne Muscular Dystrophy (DMD)
Shots:  The Disease of the Month report by PharmaShots aims to integrate an advanced approach to disease analysis. The report delves deep into the epidemiology, market size, disease management, available therapies, and key players involved   For the April edition of the Disease of the Month report, PharmaShots brings an enlightening guide to Duchenne Muscular Dystrophy,…
April 17, 2024
Insights+ The US FDA New Drug Approvals in March 2024
Insights+: The US FDA New Drug Approvals in March 2024
Shots:  PharmaShots has compiled a list of US FDA-approved drugs in the month of March 2024  The US FDA approved a total of 14 drugs including 12 new molecular entities and 2 biologics leading to the treatments for patients and advances in the healthcare industry    The major highlighted drug was BeiGene’s Tevimbra for treating Advanced…
April 15, 2024
Insights+ Key Biosimilars Events of March 2024
Insights+ Key Biosimilars Events of March 2024
Shots:   Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency    Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and patients    During March, Sandoz received the US FDA’s approval for Wyost & Jubbonti.…
April 3, 2024
PharmaShots' Key Highlights of First Quarter 2024
PharmaShots’ Key Highlights of First Quarter 2024
Shots: The first quarter of 2024 highlights major acquisitions in the pharma and biotech industry along with clinical trial results and approvals. The highlight of the quarter was Gilead's acquisition of CymaBay Therapeutics for an aggregate of ~$4.3B This quarter also showcased multiple clinical trial results including Axsome Therapeutics P-III results for AXS-12 and BMS'…
April 1, 2024
New Drug Designations - February 2024
New Drug Designations – February 2024
Shots: PharmaShots' designation report provides a concise overview of several drugs and their designations by the US FDA, and EC. This month’s report includes designations allotted to 13 small molecules, 20 biologics, and 2 devices  SN Bioscience’s SNB-101 received ODD from the US FDA for the treatment of pancreatic cancer based on preclinical results. It…
March 28, 2024
Know Your Investor (March Edition) Qiming Venture Partners
Know Your Investor (March Edition): Qiming Venture Partners
Shots: In this reprise, we feature Qiming Venture Partners again, based on the investments in 2023. With more than 600 investments to date, Qiming boasts a strong portfolio of companies involved in Technology & Consumer and Healthcare In 2023, Qiming closed 38 funding rounds comprising 11 in the first quarter, 10 in the second, 11…
March 26, 2024
Insights+ EMA Marketing Authorization of New Drugs in February 2024
Insights+: EMA Marketing Authorization of New Drugs in February 2024
Shots: The EMA approved 5 BLA and 8 New Chemical Entities in February 2024, leading to treatments for patients and advances in the healthcare industry In February 2024, the major highlighted drugs were Reblozyl to treat Transfusion-Dependent Anemia and Velsipity for the treatment of Severely Active Ulcerative Colitis PharmaShots has compiled a list of a total…
March 20, 2024
Top Performing Drug – Invega Trinza (March Edition) 
Top Performing Drug – Invega Trinza (March Edition) 
Shots:    In continuation to our previous series on the Top-Performing Drug of the month, based on 2021 revenue, this month we have selected Invega Trinza and prepared an engaging analysis for our readers    Invega Trinza (3-Months injection) is an atypical antipsychotic drug used for the treatment of schizophrenia in patients after adequately being treated with…
March 19, 2024
Insights+ The US FDA New Drug Approvals in February 2024
Insights+: The US FDA New Drug Approvals in February 2024
Shots:  PharmaShots has compiled a list of US FDA-approved drugs in the month of February 2024  The US FDA approved a total of 7 drugs including 6 new molecular entities and 1 biologic leading to the treatments for patients and advances in the healthcare industry    The major highlighted drug was Takeda’s Eohilia (budesonide oral suspension) for treating eosinophilic…
March 13, 2024
Disease of the Month - Alport Syndrome
Disease of the Month – Alport Syndrome
Shots: To keep our readers acquainted with several disease conditions, ongoing trials, and available treatment options, PharmaShots brings every month a detailed take on a particular disease after thorough research  In the next installment to our disease report, this month we have covered a detailed analysis of Alport Syndrome, which is a rare genetic disorder…
March 11, 2024
Load more

Sign Up to Our Newsletter

Be the first to know the latest updates

[mc4wp_form id="13387" element_id="style-1"]